RENAAL

RENAAL

Nephrology A clinical trial–Reduction in Endpoints in patients with Non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan. See Losartan.
Mentioned in ?
References in periodicals archive ?
Brenner BM, Cooper ME, de Zeeuw D, et al; RENAAL Study Investigators.
Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials.
Based on the results of four major renal outcome studies (Micro-HOPE, IRMA-2, RENAAL, IDNT studies), the American diabetes association has recommended ARBs for treatment of overt diabetic nephropathy, whereas patients with only microalbuminuria are recommended to be treated with either ACE inhibitors or ARBs10,11.
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL.
For the RENAAL Study Group Effects of Blood Pressure Level on Progression of Diabetic Nephropathy.
Post hoc analyses of a subset of participants in the RENAAL (Reduction of Endpoints in Non Insulin Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan) trial compared 24-h urine protein, 24-h urine albumin, and albumin:creatinine ratios for their association with renal function decline (51).
Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al; for the RENAAL Study Investigators.
The RENAAL study by Merck / Banyu was the first such trial to be successfully used in support of an approval in 2006.
Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
This approval is based on the results from the international clinical trial called RENAAL (Reduction of Endpoint in NIDDM with A-II Antagonist Losartan), which covered 1,513 type-2 diabetics (including 96 Japanese patients).
Recientemente un estudio denominado RENAAL demostro que el tratamiento mediante losartan (un antihipertensivo) retrasa la progresion de la enfermedad renal terminal, condicion que requiere de dialisis o transplante para sobrevivir", puntualizo.
Many physicians, however, use lower doses in order to lessen the hyperkalemia risk, despite outcome studies such as RENAAL, IDNT and IRMA2 not showing that lower doses of ARBs provide this renoprotective benefit," added Dr.